All Blogs

Jan 24, 2025

The 43rd Annual J.P. Morgan Healthcare Conference in 2025 showcased the accelerating progress of cell and gene therapies, reaffirming their transformative potential in modern medicine. Despite prior challenges, the field is now demonstrating tangible success, heralding a new era in treating complex and previously u...

Jan 24, 2025

The 2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry’s largest consolidation wave in recent years.  The M&A rebound in the healthcare sector has been years in the making, as pharma giants like J&J, GSK, and others face looming patent cliffs, threaten...

Jan 24, 2025

The pipeline for Graves’ disease drug treatments is rapidly expanding, with prominent companies such as Immunovant, Viridian Therapeutics, Argenx, Tourmaline Bio, Hoffmann-La Roche, and Sling Therapeutics spearheading the development of targeted therapies for thyroid disorders. Promising candidates in the late stag...

Jan 23, 2025

Tempus Announced the National Launch of the FDA-Approved xT CDx Test  On January 15, 2025, Tempus AI, Inc., a technology company driving the use of AI to advance precision medicine and improve patient care, announced the nationwide launch of its FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Th...

Jan 22, 2025

In today’s fast-paced world, healthcare mobility solutions are transforming the way care is delivered, making it smarter, faster, and more accessible than ever. From real-time patient monitoring and seamless teleconsultations to efficient appointment management and medication tracking, these solutions are bridging ...

Jan 21, 2025

FDA Approves LUMAKRAS and VECTIBIX for KRAS G12C-Mutated Colorectal Cancer Amgen has secured FDA approval for LUMAKRAS (sotorasib) in combination with VECTIBIX (panitumumab) as a treatment for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxalip...

Jan 20, 2025

Thyroid eye disease is a rare but serious autoimmune condition that affects the eyes, often linked to hyperthyroidism or Graves’ disease. Around 25-50% of people with Graves’ disease develop TED, with women being more commonly affected than men.  There were 1.4 million diagnosed prevalent cases of TED in 20...

Jan 17, 2025

Affecting around 1 in 200 people, Graves’ disease is the most common cause of an overactive thyroid. More than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. As per DelveInsight’s estimates, Graves’ disease...

Jan 17, 2025

Acute Kidney Injury (AKI) is a significant medical condition that affects millions of individuals worldwide each year. It is a rapidly progressive condition that requires timely diagnosis and treatment to prevent severe complications or long-term consequences. AKI is particularly prevalent in hospitalized patients,...

Jan 16, 2025

Acute kidney injury is a sudden and severe condition characterized by the rapid loss of kidney function, resulting in the accumulation of waste products in the blood and imbalances in fluids and electrolytes. It is often caused by factors such as severe dehydration, infections, certain medications, or complications...